Pharmaron (300759.SZ) Projects H1 Profit Decline: Net Income Forecast at 679M-713M Yuan Amid 36%-39% Drop
Stock Track
Jul 15
Pharmaron (300759.SZ) has unveiled its preliminary financial results for the first half of 2025, signaling a significant downturn in profitability. The company anticipates net profit attributable to shareholders will range between 679 million yuan and 713 million yuan, reflecting a sharp year-on-year contraction of 36% to 39%. This downward trajectory contrasts with a robust performance in non-recurring items-adjusted earnings, which are projected to climb 34% to 39% year-on-year, landing between 624 million yuan and 647 million yuan. The divergent trends highlight operational headwinds impacting core profitability despite resilience in adjusted performance metrics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.